Lexaria Bioscience (LEXX) Projected to Post Earnings on Friday

Lexaria Bioscience (NASDAQ:LEXX) is projected to issue its quarterly earnings data before the market opens on Friday, July 11th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.17 million for the quarter.

Lexaria Bioscience (NASDAQ:LEXX) last issued its quarterly earnings results on Monday, April 14th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.14 million. Lexaria Bioscience had a negative return on equity of 111.84% and a negative net margin of 1,784.03%. On average, analysts expect Lexaria Bioscience to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexaria Bioscience Stock Up 0.7%

Shares of LEXX opened at $0.89 on Thursday. The business has a 50-day simple moving average of $0.99 and a two-hundred day simple moving average of $1.44. The stock has a market cap of $15.56 million, a price-to-earnings ratio of -1.50 and a beta of 0.79. Lexaria Bioscience has a 52 week low of $0.82 and a 52 week high of $4.38.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price target on Lexaria Bioscience from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, July 1st.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.